^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MQ710

    i
    Associations
    News

    Trials

    Company:
    Imvaq Therap
    Drug class:
    Immunostimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer (NCT05859074)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    02/15/2024
    Initiation :
    05/04/2023
    Primary completion :
    05/04/2028
    Completion :
    05/04/2028
    BRAF
    |
    PD-L1 expression • BRAF mutation
    |
    Keytruda (pembrolizumab) • MQ710